Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: A pilot study

International Journal of Cardiology

Volumn 158, Issue 1, 2012, Pages 160-162

  Dominguez Rodriguez, Alberto ^a   Consuegra Sanchez, Luciano ^b   Blanco Palacios, Gabriela ^a   Abreu Gonzalez, Pedro ^c   Sanchez Grande, Alejandro ^a   Bosa Ojeda, Francisco ^a   Kaski, Juan Carlos ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Servicio de Anestesiología y Reanimación   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute coronary syndrome; Anti inflammatory; C reactive protein; Inflammation; Ivabradine

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART RATE; HUMAN; LETTER; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION;

EID: 84862008195     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.04.076     Document Type: Article

References (14)

1. A.M. Wilson, M.C. Ryan, and A.J. Boyle The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen Int J Cardiol 106 2006 291 297
2. B. Amasyali, S. Kose, H. Kursaklioglu, T. Celik, and A. Iyisoy C-reactive protein in acute coronary syndromes: a perfect trigger or an excellent indicator? Int J Cardiol 131 2008 134 135
3. D. Tousoulis, N. Papageorgiou, G. Latsios, G. Siasos, C. Antoniades, and C. Stefanadis C-reactive protein and endothelial dysfunction: gazing at the coronaries Int J Cardiol 152 2011 1 3
4. W. Koenig Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein Int J Cardiol 98 2005 199 206
5. D. DiFrancesco, and J.A. Camm Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease Drugs 64 2004 1757 1765
6. F. Custodis, M. Baumhäkel, and N. Schlimmer Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice Circulation 117 2008 2377 2387
7. J.P. Bassand, C.W. Hamm, and D. Ardissino Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
8. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and J.C. Kaski Inflammatory systemic biomarkers in setting acute coronary syndromes - effects of the diurnal variation Curr Drug Targets 10 2009 1001 1008
9. A. Dominguez-Rodriguez, and P. Abreu-Gonzalez C-reactive protein and endothelial dysfunction: the clinicians should have in mind diurnal variations Int J Cardiol 154 2012 353
10. M. Baumhäkel, F. Custodis, N. Schlimmer, U. Laufs, and M. Böhm Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice Atherosclerosis 212 2010 55 62
11. A. Drouin, M.E. Gendron, E. Thorin, M.A. Gillis, F. Mahlberg-Gaudin, and J.C. Tardif Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice Br J Pharmacol 154 2008 749 757
12. S.H. Schirmer, A. Degen, and M. Baumhäkel Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis Eur Heart J 2011 [Epub ahead of print]
13. F. Custodis, S.H. Schirmer, M. Baumhäkel, G. Heusch, M. Böhm, and U. Laufs Vascular pathophysiology in response to increased heart rate J Am Coll Cardiol 56 2010 1973 1983
14. A. Dominguez-Rodriguez, G. Blanco-Palacios, and P. Abreu-Gonzalez Increased heart rate and atherosclerosis: potential implications of ivabradine therapy World J Cardiol 3 2011 101 104